Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
World J Diabetes ; 13(11): 940-948, 2022 Nov 15.
Article in English | MEDLINE | ID: mdl-36437863

ABSTRACT

Non-healing diabetic foot ulcers (DFU) are the most notable and striking complications of diabetes mellitus. More than 25% of nonhealing DFU can ultimately lead to amputation of the lower extremity within 6-18 mo after the first manifestation of the wound. Although wound healing is complex, nutritional status is crucial in soft tissue repair. Malnutrition is highly prevalent and overlooked in patients with diabetes and chronic wounds. Moreover, to date, we do not have clear recommendations or evidence about the use of nutritional supplements for improving wound healing in patients with DFU. In this article the authors briefly analyzed the current evidence on the use of nutritional supplements of proteins or amino acids, fatty acids, probiotics, vitamins, and trace elements in the wound healing process in patients with DFU.

2.
Clin Sci (Lond) ; 134(17): 2337-2352, 2020 09 18.
Article in English | MEDLINE | ID: mdl-32857135

ABSTRACT

BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) has attracted attention not only as an anti-cancer agent, but also as a potential treatment for diabetes. Animal studies have shown that TRAIL delivery ameliorated glucose control in type 1 and type 2 diabetes. It is currently unknown whether TRAIL positive effects are maintained in more severe forms of type 2 diabetes, and whether they include renoprotection. Our study aimed at evaluating TRAIL effects in a severe form of type 2 diabetes with nephropathy. MATERIALS AND METHODS: A total of 20 db/db mice were treated with saline or TRAIL twice per week for 12 weeks. In parallel, renal tubular epithelial cells were cultured with TGF-ß1 in the presence and absence of TRAIL, with and without silencing TRAIL-specific receptor (DR5) and leptin receptor. RESULTS: TRAIL did not improve glucose control, but it significantly reduced circulating interleukin (IL)-6 and resistin. In the kidney, TRAIL treatment significantly ameliorated glomerular and tubular morphology with an improvement in kidney function, but no effect on proteinuria. Our in vitro studies on TGF-ß1-treated cells, showed that by binding to DR5, TRAIL rescued normal tubular cell morphology, increasing E-cadherin and reducing α-smooth muscle actin (SMA) expression, with no effects on cell viability. Interestingly, both in vivo and in vitro, TRAIL reduced the accumulation of the autophagy substrate p62. CONCLUSIONS: Our data confirm TRAIL protective effects against organ damage and shed light on to promising anti-fibrotic actions, which are independent of glucose control. TRAIL anti-fibrotic actions might be due to the rescue of autophagy in diabetes.


Subject(s)
Diabetic Nephropathies/pathology , Epithelial-Mesenchymal Transition , Kidney/pathology , TNF-Related Apoptosis-Inducing Ligand/pharmacology , Transforming Growth Factor beta/pharmacology , Animals , Body Weight/drug effects , Diabetic Nephropathies/metabolism , Epithelial-Mesenchymal Transition/drug effects , Feeding Behavior/drug effects , Fibrosis , Gene Expression Regulation/drug effects , Gene Silencing/drug effects , Glucose/metabolism , Humans , Inflammation/pathology , Kidney/drug effects , Kidney/physiopathology , Kidney Tubules/drug effects , Kidney Tubules/pathology , Kidney Tubules/physiopathology , Male , Mice , Protein Binding/drug effects , Rats , Receptors, Leptin/metabolism , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , Sequestosome-1 Protein/metabolism
3.
BMC Endocr Disord ; 18(1): 86, 2018 Nov 19.
Article in English | MEDLINE | ID: mdl-30453922

ABSTRACT

BACKGROUND: Thyroid lymphomas are an exceptional finding in patients with thyroid nodules. Burkitt's lymphoma is one of the rarest and most aggressive forms of thyroid lymphomas, and its prognosis depends on the earliness of medical treatment. Given the rarity of this disease, making a prompt diagnosis can be challenging. For instance, fine-needle aspiration (FNA) cytology, which is the first-line diagnostic test that is performed in patients with thyroid nodules, is often not diagnostic in cases of thyroid lymphomas, with subsequent delay of the start of therapy. CASE PRESENTATION: Here we report the case of a 52-year-old woman presenting with a rapidly enlarging thyroid mass. Thyroid ultrasonography demonstrated a solid hypoechoic nodule. FNA cytology was only suggestive of a lymphoproliferative disorder and did not provide a definitive diagnosis. It is core needle biopsy (CNB) that helped us to overcome the limitations of routine FNA cytology, showing the presence of thyroid Burkitt's lymphoma. Subsequent staging demonstrated bone marrow involvement. The early start of an intensive multi-agent chemotherapy resulted in complete disease remission. At 60 months after the diagnosis, the patient is alive and has not had any recurrence. CONCLUSIONS: Clinicians should be aware that thyroid Burkitt's lymphoma is an aggressive disease that needs to be treated with multi-agent chemotherapy as soon as possible. To diagnose it promptly, they should consider to order/perform a CNB in any patient with a rapidly enlarging thyroid mass that is suspicious for lymphoma.


Subject(s)
Burkitt Lymphoma/pathology , Thyroid Gland/pathology , Thyroid Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biopsy, Large-Core Needle/methods , Burkitt Lymphoma/diagnostic imaging , Female , Humans , Middle Aged , Thyroid Gland/diagnostic imaging , Thyroid Gland/drug effects , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/drug therapy , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/drug therapy
4.
Endocrine ; 57(3): 402-408, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27848197

ABSTRACT

PURPOSE: Radiofrequency ablation has been advocated as an alternative to radioiodine and/or surgery for the treatment of autonomously functioning benign thyroid nodules. However, only a few studies have measured radiofrequency ablation efficacy on autonomously functioning benign thyroid nodules. The aim of this work was to evaluate the 12-month efficacy of a single session of radiofrequency ablation (performed with the moving shot technique) on solitary autonomously functioning benign thyroid nodules. METHODS: Thirty patients with a single, benign autonomously functioning benign thyroid nodules, who were either unwilling or ineligible to undergo surgery and radioiodine, were treated with radiofrequency ablation between April 2012 and May 2015. All the patients underwent a single radiofrequency ablation, performed with the 18-gauge needle and the moving shot technique. Clinical, laboratory, and ultrasound evaluations were scheduled at baseline, and after 1, 3, 6, and 12 months from the procedure. RESULTS: A single radiofrequency ablation reduced thyroid nodule volume by 51, 63, 69, and 75 % after 1, 3, 6, and 12 months, respectively. This was associated with a significant improvement of local cervical discomfort and cosmetic score. As for thyroid function, 33 % of the patients went into remission after 3 months, 43 % after 6 months, and 50 % after 12 months from the procedure. This study demonstrates that a single radiofrequency ablation allowed us to withdraw anti-thyroid medication in 50 % of the patients, who remained euthyroid afterwards. CONCLUSION: This study shows that a single radiofrequency ablation was effective in 50 % of patients with autonomously functioning benign thyroid nodules. Patients responded gradually to the treatment. It is possible that longer follow-up studies might show greater response rates.


Subject(s)
Ablation Techniques/adverse effects , Hyperthyroidism/prevention & control , Hypothyroidism/prevention & control , Radiofrequency Therapy , Thyroid Gland/surgery , Thyroid Nodule/surgery , Aged , Cohort Studies , Female , Follow-Up Studies , Humans , Hyperthyroidism/etiology , Hypothyroidism/etiology , Italy , Male , Neoplasm Grading , Organ Sparing Treatments/adverse effects , Patient Acceptance of Health Care , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Prospective Studies , Radio Waves/adverse effects , Remission Induction , Thyroid Gland/blood supply , Thyroid Gland/diagnostic imaging , Thyroid Gland/physiopathology , Thyroid Nodule/blood supply , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/physiopathology , Tumor Burden/radiation effects , Ultrasonography
5.
J Diabetes Res ; 2016: 8917578, 2016.
Article in English | MEDLINE | ID: mdl-27652272

ABSTRACT

Since the advent of insulin, the improvements in diabetes detection and the therapies to treat hyperglycemia have reduced the mortality of acute metabolic emergencies, such that today chronic complications are the major cause of morbidity and mortality among diabetic patients. More than half of the mortality that is seen in the diabetic population can be ascribed to cardiovascular disease (CVD), which includes not only myocardial infarction due to premature atherosclerosis but also diabetic cardiomyopathy. The importance of renin-angiotensin-aldosterone system (RAAS) antagonism in the prevention of diabetic CVD has demonstrated the key role that the RAAS plays in diabetic CVD onset and development. Today, ACE inhibitors and angiotensin II receptor blockers represent the first line therapy for primary and secondary CVD prevention in patients with diabetes. Recent research has uncovered new dimensions of the RAAS and, therefore, new potential therapeutic targets against diabetic CVD. Here we describe the timeline of paradigm shifts in RAAS understanding, how diabetes modifies the RAAS, and what new parts of the RAAS pathway could be targeted in order to achieve RAAS modulation against diabetic CVD.


Subject(s)
Angiotensin II Type 2 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Atherosclerosis/drug therapy , Cardiovascular Diseases/drug therapy , Diabetic Cardiomyopathies/drug therapy , Atherosclerosis/etiology , Atherosclerosis/prevention & control , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Diabetic Cardiomyopathies/prevention & control , Humans
6.
BMC Nephrol ; 17(1): 65, 2016 07 07.
Article in English | MEDLINE | ID: mdl-27389397

ABSTRACT

BACKGROUND: Malignant hypertension is a condition characterized by severe hypertension and multi-organ ischemic complications. Albeit mortality and renal survival have improved with antihypertensive therapy, progression to end-stage renal disease remains a significant cause of morbidity and mortality. The underlying cause of malignant hypertension, which can be primary or secondary hypertension, is often difficult to identify and this can substantially affect the treatment outcomes, as we report here. CASE PRESENTATION: A 33-year-old woman presented with severe hypertension and acute renal failure. Initial evaluation demonstrated hyperreninemia with hyperaldosteronism and a possible renal artery stenosis at the contrast-enhanced CT scan. Although this data suggested the presence of a secondary form of hypertension, further exams excluded our first diagnosis of renal artery stenosis. Consequently, the patient did not undergo renal angiography (and the contrast media infusion associated with it), but she continued to be medically treated to achieve a tight blood pressure control. Our conservative approach was successful to induce renal function recovery over 2 years of follow-up. CONCLUSION: This case highlights the difficulty in differentiating between primary and secondary forms of malignant hypertension, particularly when the patient presents with acute renal failure. Clinicians should consider renal artery ultrasound as a first level diagnostic technique, given that the presentation of primary malignant hypertension can often mimic a renal artery stenosis. Secondly, adequate control of blood pressure is essential for kidney function recovery, although this may require a long time.


Subject(s)
Acute Kidney Injury/etiology , Essential Hypertension/complications , Hypertension, Malignant/complications , Hypertension, Malignant/diagnosis , Adult , Antihypertensive Agents/therapeutic use , Essential Hypertension/drug therapy , Female , Humans , Hyperaldosteronism/blood , Hypertension, Malignant/drug therapy , Renin/blood
7.
J Renin Angiotensin Aldosterone Syst ; 16(4): 730-8, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26283678

ABSTRACT

OBJECTIVE: Experimental evidence suggests that aldosterone directly contributes to organ damage by promoting cell growth, fibrosis, and inflammation. Based on these premises, this work aimed to assess the glomerular effects of aldosterone, alone and in combination with salt. METHODS: After undergoing uninephrectomy, 75 rats were allocated to five groups: control, salt diet, aldosterone, aldosterone + salt diet, aldosterone + salt diet and eplerenone, and they were all studied for four weeks. We focused on glomerular structural, functional, and molecular changes, including slit diaphragm components, local renin-angiotensin system activation, as well as pro-oxidative and profibrotic changes. RESULTS: Aldosterone significantly increased systolic blood pressure, led to glomerular hypertrophy, mesangial expansion, and it significantly increased the glomerular permeability to albumin and the albumin excretion rate, indicating the presence of glomerular damage. These effects were worsened by adding salt to aldosterone, while they were reduced by eplerenone. Aldosterone-induced glomerular damage was associated with glomerular angiotensin-converting enzyme (ACE) 2 downregulation, with ACE/ACE2 ratio increase, ANP decrease, as well as with glomerular pro-oxidative and profibrotic changes. CONCLUSIONS: Aldosterone damages not only the structure but also the function of the glomerulus. ACE/ACE2 upregulation, ACE2 and ANP downregulation, and pro-oxidative and profibrotic changes are possible mechanisms accounting for aldosterone-induced glomerular injury.


Subject(s)
Aldosterone/pharmacology , Kidney Glomerulus/pathology , Kidney Glomerulus/physiopathology , Animals , Fibrosis , Glomerular Filtration Rate/drug effects , Kidney Glomerulus/drug effects , Male , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Rats, Wistar , Renin-Angiotensin System/drug effects , Sodium Chloride, Dietary/pharmacology
8.
GED gastroenterol. endosc. dig ; 14(5): 229-35, set.-out. 1995. tab
Article in Portuguese | LILACS | ID: lil-178567

ABSTRACT

Os autores fazem revisao dos critérios de prognósticos utilizados na pancreatite aguda, enfatizando a importância do conjunto de avaliaçoes clínico-laboratoriais e de imagem. Muitos dos diferentes critérios avaliados utilizam parâmetros comuns, para outros eles sao próprios. Discute-se qual o melhor método a ser empregado em paciente com pancreatite aguda, visando estabelecer o tratamento mais adequado e desse modo evitar a utilizaçao desnecessária de recursos e contribuir para a padronizaçao da conduta médica.


Subject(s)
Humans , Pancreatitis/diagnosis , Acute Disease , Prognosis , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...